Sign In
Buy NMRA
$1.62
+0.105 (+6.95%)
At Close: Jun 26, 2026
Neumora Therapeutics to Participate in Upcoming Conferences in November
07:00am, Monday, 30'th Oct 2023
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that
Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades
07:03pm, Wednesday, 18'th Oct 2023
The lead Neumora Therapeutics, Inc. product candidate, Navacaprent, has shown promise in treating major depressive disorder, MDD, and bipolar depression. The lead product candidate, Navacaprent, is a
Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines Dr. Lenz brings 20 yea
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
07:54pm, Thursday, 28'th Sep 2023
The IPO market in 2023 has been anything but hot. After a record-breaking year in 2021, the appetite for new listings has cooled down significantly, first in 2022 and continuing into the current year.
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
08:36am, Wednesday, 27'th Sep 2023
Amgen Inc.'s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.
Why Shares of Neumora Therapeutics Slumped This Week
06:06pm, Thursday, 21'st Sep 2023
Neumora focuses on central nervous system disorders. Its lead therapy is Navacaprant to treat MDD.
